Under this partnership, the two companies will work to optimise manufacturing processes for ADC candidates being developed by Taiho Pharmaceutical using the AraLinQ™ technology of Araris Biotech AG, a subsidiary of Taiho Pharmaceutical.

By combining Taiho Pharmaceutical’s expertise and capabilities in ADC drug discovery with Fujifilm’s process development and manufacturing technologies cultivated through its biologics CDMO business, the companies aim to achieve stable production of high-quality ADCs and enhance their global competitiveness in the next-generation ADC field.

Fujifilm operates its biologics CDMO business globally and has extensive experience and a proven track record in the process development and manufacturing of antibody therapeutics. Its group company, Fujifilm Toyama Chemical, plans to launch Japan’s first integrated ADC CDMO service in 2027 and is building a manufacturing framework capable of providing end-to-end ADC production services in Japan, from antibody production and conjugation to final drug product manufacturing.

Going forward, Taiho Pharmaceutical and Fujifilm will leverage their respective strengths under this partnership to optimise manufacturing processes for the stable production of high-quality ADCs.

In addition, as development of the target ADC candidates progresses, the companies plan to expand their technical collaboration and strengthen manufacturing technology platforms and frameworks that support sustainable supply.